Login to Your Account



Other News To Note


Thursday, September 19, 2013
ITM Isotope Technologies Munich AG, of Garching, Germany, said it entered an agreement with Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., for pharmaceutical development and commercialization of radiolabeled DOTA-conjugated somatostatin analogue DOTA-[Tyr3]-octreotide (edotreotide) for human oncology therapeutic use.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription